Ideaya partners with Gilead; Lilly extends offer for Point; Theseus lets go of CEO, CMO

Ideaya and Gilead will study a potential combo in bladder cancer. The South San Francisco-based company announced Monday that it plans to test its MAT2A inhibitor in combination with Gilead’s Trodelvy in MTAP-deletion bladder cancer. Financial terms of the agreement were not disclosed.

Eli Lilly extended its offer for Point Biopharma to Dec. 15. The tender offer was previously set to expire on Dec. 1. Lilly announced plans to buy the radiopharma in October for about $1.4 billion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

International monitor allows monkey shipments from Cambodia to continue

In a boost for one of the largest clinical research organizations in the U.S., the officials who oversee an international treaty governing endangered species voted to

February 4, 2025

JP Morgan 2025: AstraZeneca promises a ‘catalyst-rich’ year ahead – Pharmaceutical Technology

AstraZeneca CFO Aradhana Sarin promised Phase III readouts and revenue growth in 2025 despite ongoing investigations of its Chinese operations. Credit: Bloomberg/ Getty Images AstraZeneca

January 15, 2025

Enhanced mental wellbeing linked to workplace interventions on physical activity and sedentariness

The effects of six months of multi-level workplace interventions aimed at decreasing sedentary behavior.

January 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.